Regeneron: Rapidly Decreasing Importance Of Eylea

Regeneron Pharmaceuticals delivered strong Q2 results, driven by Dupixent and Libtayo growth that were enough to offset the decline of the Eylea franchise. The existing product portfolio and upcoming approvals should be more than sufficient to keep Regeneron in growth mode. The obesity pipeline expansion adds a new growth avenue for the company in the 2030s.